Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with Lilly’s latest insulin pen.
The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will pair with software and/or medical devices offered by Dexcom (NSDQ:DXCM), Glooko, myDiabby Healthcare (Bordeaux, France) and Roche, with its mySugr app, to facilitate the integration of personalized data and actionable insights.
Lilly aims to receive the CE mark for the Tempo Smart Button later in 2021 and launch the Tempo Pen and Tempo Smart Button in several markets outside the United States following this certification.
“We’re pleased to work alongside these innovative partners who share our commitment to improving diabetes outcomes by bringing together medicine and digital solutions for the global diabetes community,” said Marie Schiller, Lilly’s VP of product development for connected care and insulins, in a news release.
“Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses,” Schiller said. “By integrating data from the connected insulin pen solutions into widely used compatible software, including potential future collaborations, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection. These solutions may also help address psychological barriers like fear of hypoglycemia that may negatively impact diabetes management.”
The agreement with Glooko will pair the Tempo pen with Glooko’s software to enable the integration of personalized health data from the pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers and food logs.
“Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch,” said Glooko CEO Russ Johannesson in a separate statement. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes. We are excited about continuing to expand the availability of our solution and look forward to helping more people manage their diabetes through our innovative products.”
